Shield Therapeutics reports $6.4m in Q1 revenue, eyes cash flow positivity

LONDON - Shield Therapeutics (LON:STXS) plc (LSE:STX), a pharmaceutical company focusing on iron deficiency treatments, reported unaudited net revenues of $6.4 million for the first quarter of 2025. Despite early-year challenges, including significant weather disruptions and a 20% sales force vacancy, the company’s lead product, ACCRUFeR®, saw a substantial rebound in March, which accounted for approximately half of the quarter’s revenue.

The London-based company experienced a marked improvement in March with an average net price of $220 per ACCRUFeR® prescription, compared to an average of $187 throughout the quarter. This increase is notable when compared to the first quarter of 2024, where the average net price was $139. The total prescriptions for ACCRUFeR® in the first quarter reached about 36,800, with around 27% being consignment-based at a significantly subsidized price to patients.

Shield Therapeutics ended the quarter with cash and cash equivalents of $10.5 million and has amended the revenue covenants associated with its existing $20 million debt financing from SWK. This strategic financial move is part of Shield’s broader goal to achieve cash flow positivity by the end of 2025.

CEO Anders Lundstrom expressed confidence in the company’s trajectory, citing the recovery in prescription growth, a fully staffed sales force, and strong execution across the business. Lundstrom highlighted the company’s progress in global markets, including recent milestones in Canada, China, and the pediatric program, as evidence of ACCRUFeR®’s growing value and Shield’s commitment to expanding patient access worldwide.

The company is scheduled to release its audited full-year results by the end of April 2025 and will host a live online presentation via the Investor Meet Company platform to discuss the Q1 2025 update. This event will allow both existing and potential investors to engage with the company’s CEO and CFO and submit questions.

The information presented in this article is based on a press release statement from Shield Therapeutics plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.